|
N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4 methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide |
|---|---|
| Trade Name | |
| Orphan Indication | Neuroblastoma |
| EU Market Approval | EU |
| EU Designation Date | 2015-11-11 00:00:00 |
| Sponsor | Pharma Gateway AB |
Related Access Program
South Plains Oncology Consortium – Recurrent Neuroblastoma
Catalyst Pharmaceuticals, Inc. – Downbeat Nystagmus
South Plains Oncology Consortium – Neuroblastoma
British Columbia Cancer Agency – Neuroblastoma
South Plains Oncology Consortium – Neuroblastoma
Children’s Hospital of Philadelphia – Neuroblastoma
University of California, San Francisco – Neuroblastoma
Jubilant DraxImage Inc. – Neuroblastoma
Children’s Hospital Medical Center, Cincinnati – Neuroblastoma
Apeiron Biologics AG – Neuroblastoma
